Age and Race May Determine Whether Cancer Patients Access Their Electronic...
A single-center study showed that certain cancer patients were less likely to enroll in a patient portal that allows them to access their electronic health records (EHRs). The study was published in...
View ArticleChronic Myeloid Leukemia: What Your Patients Need to Know
Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, accounts for about 15% of adult leukemia cases.¹ One of the rarest types of leukemia, CML starts in the bone marrow and...
View ArticleResponse-Based Ponatinib Dosing Appears Effective in Chronic Phase Chronic...
The following article features coverage from the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Click here to read more of Cancer Therapy Advisor‘s conference coverage....
View ArticleCML: COVID-19 May Be Fatal in More Than 5% of Patients
The following article features coverage from the European Hematology Association (EHA) 2021 Virtual Congress. Click here to read more of Cancer Therapy Advisor‘s conference coverage. The mortality...
View ArticleUnderdosing in Patients With Cancer and Obesity: A Thing of the Past?
Updated guidelines1 recommend that patients with cancer and obesity receive the full approved doses of immunotherapy and targeted therapies, but do oncologists agree with this approach? In the past,...
View ArticleThe Past, Present, and Future of GRASP: Connecting Cancer Researchers,...
A patient-led initiative is connecting cancer patients with clinicians and researchers, allowing these parties to exchange ideas and learn from each other, according to the co-founder of the...
View ArticleClosing the Gap Between Cancer Patients and Researchers: A Patient Advocate’s...
Though cancer research is focused on helping patients — improving their survival and quality of life — there is often a gap in communication between researchers and patients. A patient-led initiative...
View ArticleASCO and Friends: Cancer Patients Should Be Included in COVID-19 Vaccine Trials
Cancer patients and survivors should be included in COVID-19 vaccine trials unless there is a safety justification for excluding them, according to a statement from the American Society of Clinical...
View ArticleTherapeutic Drug Monitoring Improved Incidence of Pleural Effusion With...
A therapeutic drug monitoring (TDM) approach to treatment with dasatinib was shown to be associated with reduced rates of pleural effusion in patients treated for newly diagnosed chronic phase-chronic...
View ArticleRegistry Data Support Use of Ponatinib in CML, Ph+ ALL Resistant or...
A study of prospective registry data supported routine ponatinib use in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who...
View ArticleChanges in Clinical Trial Conduct Prompted by the COVID-19 Pandemic Should...
The COVID-19 pandemic prompted changes to standard practices for cancer clinical trials, and thought leaders have recommended continuing — and improving upon — those new practices. These...
View ArticleNew-Generation BCR-ABL TKIs Linked to Increased Risk of Hepatotoxicity in...
Drug-induced hepatotoxicity is a concern because half of the currently available oral drugs are associated with hepatotoxicity, including some used to treat chronic myeloid leukemia (CML). A team of...
View ArticleSurvey Reveals ‘Striking’ Barriers to Accessing High-Priority Cancer Drugs
An international survey has revealed barriers to accessing cancer drugs deemed essential for routine clinical care. The survey was published in The Lancet Oncology. Researchers surveyed medical...
View ArticleAlgorithm Assesses Risk of Major Adverse Cardiovascular Events in TKI-Treated...
Patients with chronic myeloid leukemia (CML) who are treated with certain tyrosine kinase inhibitors (TKIs) may have a greater risk for adverse cardiovascular events. But healthcare providers do not...
View ArticleScemblix Approved for Ph+ Chronic Myeloid Leukemia in Chronic Phase
The Food and Drug Administration (FDA) has granted accelerated approval to Scemblix® (asciminib) for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in...
View ArticleComparison of Generic and Branded Imatinib for Patients With Chronic Myeloid...
A recent systematic review of 36 studies suggests that generic imatinib has performed similarly to branded imatinib with regard to efficacy and safety in the treatment of chronic myeloid leukemia...
View ArticleFactors That Impact HRQOL in Pediatric Patients With Chronic Myeloid Leukemia
Several factors may impact health-related quality of life (HRQOL) in children with chronic phase chronic myeloid leukemia (CML), according to a study published in the Journal of Cancer Research and...
View ArticleAnkle-Brachial Index, Cardiac Ankle Vascular Index May Indicate Risk of...
Clinical management of patients with chronic myelogenous leukemia (CML) who are receiving tyrosine kinase inhibitors (TKIs) may be improved by assessing ankle-brachial blood pressure index (ABI) and...
View ArticleSeroconversion After COVID-19 Vaccination High in CML, Low in NHL
The following article features coverage from the 2021 American Society of Hematology Annual Meeting. Click here to read more of Cancer Therapy Advisor’s conference coverage. About 15% of patients with...
View ArticleAsciminib Continues to Demonstrate Superior Efficacy vs Bosutinib in Chronic...
The following article features coverage from the 2021 American Society of Hematology Annual Meeting. Click here to read more of Cancer Therapy Advisor’s conference coverage. An updated analysis of the...
View Article